Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation

Transplantation

Volumn 81, Issue 8, 2006, Pages 1153-1156

  Frisaldi, Elisa ^a   Conca, Raffaele ^b   Magistroni, Paola ^b   Fasano, Maria Edvige ^b   Mazzola, Gina ^b   Patanè, Francesco ^b   Zingarelli, Edoardo ^b   Dall'Omo, Anna M ^b   Brusco, Alfredo ^a   Amoroso, Antonio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

CD30; Heart transplantation; Polymorphisms; Scd30

Indexed keywords

CD30 ANTIGEN;

ALLELE; ARTICLE; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC TRANSCRIPTION; HEART TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; FEMALE; HEART TRANSPLANTATION; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 33646800851     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000205181.31604.09     Document Type: Article

References (17)

1. Süsal C, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
2. Süsal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003; 76(8): 1231.
3. Pelzl S, Opelz G, Daniel V, et al. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75(3): 421.
4. Dürkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic of Hodgkin's disease. Cell 1992; 68(3): 421.
5. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457.
6. Tarkowski M. Expression and role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003; 10: 267.
7. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 156(5): 1723.
8. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000; 156(5): 1479.
9. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plot: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561.
10. Süsal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic testing in kidney Transplantation. Transplant Proceed 2004; 36: 29.
11. Nakao K, Nagake Y, Okamoto A, et al. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 2002; 91(2): 215.
12. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavourable outcome. Blood 1998; 91: 3011.
13. + T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001; 22: 72.
14. Gerli R, Monti D, Bistoni O, et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Devel 2001; 121(1-3): 37.
15. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3.
16. Di Lorenzo G, Gangemi S, Merendino RA, et al. Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and scoring Atopic Dermatits index. Mediators Inflamm 2003; 12(2): 123.
17. Matinlauri IH, Kyllönen LEJ, Salmela KT, et al. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 2005; 80(12): 1809.